Evidence map›Paper›PMID 41127439›Full record

ArticleStatistics in biopharmaceutical research2025

On the Two-Step Hybrid Design for Augmenting Randomized Trials Using Real-World Data.

Jiapeng Xu, Ruben P A van Eijk, Alicia Ellis, Tianyu Pan, Lorene M Nelson, Kit C B Roes, Marc van Dijk, Maria Sarno, Leonard H van den Berg, Lu Tian and 1 more

Abstract read
In one paragraph

Article in Statistics in biopharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiapeng XuDepartment of Biomedical Data Science and Center for Innovative Study Design, Stanford University School of Medicine, California, CA.
Ruben P A van EijkDepartment of Biomedical Data Science and Center for Innovative Study Design, Stanford University School of Medicine, California, CA.
Alicia EllisUCB Pharma, Brussels, Belgium.
Tianyu PanDepartment of Biomedical Data Science and Center for Innovative Study Design, Stanford University School of Medicine, California, CA.
Lorene M NelsonDepartment of Epidemiology and Population Health, Stanford University School of Medicine, California, CA.
Kit C B RoesDepartment of IQ Health - Biostatistics, Radboud University Medical Center, Nijmegen, The Netherlands.
Marc van DijkUCB Pharma, Brussels, Belgium.
Maria SarnoUCB Pharma, Brussels, Belgium.
Leonard H van den BergDepartment of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, The Netherlands.
Lu TianDepartment of Biomedical Data Science and Center for Innovative Study Design, Stanford University School of Medicine, California, CA.ORCID 0000-0002-5893-0169
Ying LuDepartment of Biomedical Data Science and Center for Innovative Study Design, Stanford University School of Medicine, California, CA.ORCID 0000-0002-7698-8962

Funding

Stanford Center for Clinical and Translational Research and EducationUM1TR004921 · NCATS · STANFORD UNIVERSITY · PI MANISHA DESAI, DEAN W FELSHER · 2024 to 2026
$30.1M
Translational Biology CoreP01CA257907 · NCI · STANFORD UNIVERSITY · PI Maximilian Diehn, Quynh-Thu Xuan Le · 2022 to 2026
$12.0M
Statistical Methods for Optimizing Personalized Treatment SelectionR01HL089778 · NHLBI · STANFORD UNIVERSITY · PI LU TIAN · 2008 to 2026
$4.8M
NCATS NIH HHS UM1 TR004921NCI NIH HHS P01 CA257907NHLBI NIH HHS R01 HL089778
6 · The paper itself

Abstract

Hybrid clinical trials, which borrow real-world data (RWD) from patient registries, claims databases, or electronic health records (EHRs) to augment randomized clinical trials, are of increasing interest. Hybrid clinical trials are especially relevant for rare diseases, where the recruitment of large sample sizes may be challenging. While these trials may better use available information, they assume that the RWD and randomized control arm are exchangeable. Violating this assumption can induce bias, inflate Type I error, or adversely affect statistical power. A two-step hybrid design first tests the exchangeability between randomized control arm and external data sources before incorporating RWD as a comparator for statistical inferences (Yuan et al. 2019). This approach reduces the chance of inappropriate borrowing but may simultaneously inflate the Type I error rate. We propose four different methods to control the Type I error rate under the exchangeability assumption. Approach 1 estimates the variance of the overall test statistic and rejects the null hypothesis based on a Z-test. Approach 2 uses a numerical method to determine the exact critical value for Type I error control. Approach 3 splits the Type I error rates according to the equivalence test outcome. Approach 4 adjusts the critical value only when equivalence is established. We illustrate these methods using a hypothetical scenario in the context of amyotrophic lateral sclerosis (ALS). We evaluate the Type I error and power under various clinical trial conditions in comparison with the Bayesian power prior approach (Ibrahim et al. 2015). We demonstrate that our proposed methods and Bayesian power prior control Type I error and increase power under the exchangeability assumption, whereas the method proposed by Yuan et al. (2019) results in an increased Type I error. In the scenario where the exchangeability assumption does not hold, all methods fail to control the Type I error. Our proposed methods, however, limit a maximum Type I error inflation ranging from 6% to 8%, which compares favorably to 10% for Yuan et al. (2019) and 16% for the Bayesian power prior. All methods increase statistical power under the exchangeability condition but may lead to a loss of statistical power when the exchangeability assumption is violated.

Indexed as

Amyotrophic lateral sclerosisConditional borrowingHybrid clinical trialsReal-world data (RWD) randomized controlled clinical trialsTest-then-poolType I error

Identifiers

PMID41127439
PMCPMC12539643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.